Cyberonics reneged on its "Lifetime Reimbursement Guarantee". Click on the image to learn how you can help...

Sunday, April 29, 2012

When meds fail, magnetic therapy shows promise for treating depression

When meds fail, magnetic therapy shows promise for treating depression

6:54 PM, Apr. 27, 2012 

Dr. Amit Anand demonstrates the TMS device on Patty Harshaw, his department's TMS coordinator. / Doug McSchooler / For the Star
The depressed part of Ruth Schwer's brain told her that nothing would help, nothing would break through the stifling malaise. She had tried medications. Each worked for six months to a year, but then, the effect would wear off, and she would plummet back into darkness.

Still, the thinking side of her brain told Schwer, 43, to keep looking for a treatment.

"I felt more and more desperate," she said. "But the rational part says that you've experienced this before, you know it will change."

Then, she found a therapy unlike any other she had tried -- transcranial magnetic stimulation, known as TMS.

The treatment delivers magnetic pulses that produce electricity in her brain. While no one knows for sure how it works, the pulses appear to correct a deficit in the brain's chemical makeup, which over time results in a lifting of the depression.

Approved for use by the Food and Drug Administration four years ago, TMS gives psychiatrists their first-ever tool for patients for whom medications don't work or produce too many side effects. It is not as drastic as electro-convulsive therapy, which can interfere with a person's memory and is usually reserved for people with the most severe forms of depression.

For patients like Schwer, who lives on the Northwestside, TMS can be life-changing.

Schwer has a master's degree and a full-time job. But since puberty, she has grappled with periods of depression that leave her bedridden and isolated.

In the summer of 2010, she decided to try the treatment, which consists of half-hour or so sessions every day for four to six weeks.

Patients settle into a spa chair, and the doctor positions the magnet, a C-shaped device a little larger than the span of your hand, over the left side of the skull, next to the part of the brain that governs mood.

The NeuroStar TMS machine then administers treatment for four seconds, rests for 26 seconds and fires again. The pulses are thought to stimulate the neurons in the area, which prods them to release neurotransmitters, which over time will improve mood in many patients.

Depression doesn't stem from a lack of one chemical in the brain but from the workings of the brain's circuit as a whole, doctors think.

"It's the same as how electricity is produced through turbines. . . . The brain is also a conducting organ," said Dr. Amit Anand, director of the TMS and mood disorders programs at Indiana University Health. "It is a different way of thinking about depression. . . . We can straight away treat the organ, the brain, which is involved in depression, rather than the whole body."

The treatment sensation is not pleasant, say some who have gone through it. It's like "noogies," said Dr. Christopher Bojrab, a psychiatrist in private practice in Indianapolis, who has tried it.

As compared with other therapies, including medications, side effects other than the discomfort are minimal, experts say. A very small number of cases have resulted in seizures.

Schwer recalled it feeling more like a woodpecker sitting inside her temple.

"The odd thing is that the pressure was coming from the inside of your head, not the outside," she said.

Over time, however, she got used to the sensation, and it did not bother her.

Then about the third week of treatment, she woke up one day and realized she was smiling.

"I realized I had the freedom to direct my attention to where I wanted it to go," she said. "Having the option to experience happiness and joy, I felt like something had definitely changed for me."

Schwer remains on medication, but at a lower dose. And most exciting, her prescription has not changed for more than a year. She said it's easier to interact with strangers or try new things, like signing up for an African drumming class.

In the past year, she was also able to undergo surgery to correct her congenitally malformed hips.
"I felt like there was a point to getting better," she said. "In my previous mental state, I would have said, 'Yes, I'm in pain, but what does it matter? It's not going to get better, you just have to live with it.' "

TMS may not be for everybody. Treatments aren't cheap, and many insurers don't cover it. Patients can expect to pay upwards of $6,000.

Nor does it help everybody. To qualify, one must have tried and failed to address the depression with medication.

About a third of those people who try TMS will see their symptoms completely disappear, said Dr. Mark George, a spokesman for the American Psychiatric Association, who has studied TMS since 1993.

Once people have undergone treatment, they may need a follow-up session or two, but some people enjoy results for years. And, if they return five or six years later, undergoing therapy again often helps, said George, a research psychiatrist at the Medical University of South Carolina.

Bojrab, who has been offering the therapy for about two years, said that none of the 20 patients he's treated has returned. Out of those 20, three showed no response, half had a good response, and seven enjoyed complete remission; some even stopping their medications.

Before she underwent the treatment at IU Health, Jan Tobias, 56, had hoped she would fall in the latter camp. More than halfway through, it became clear that would not be the case.

Nor did she experience what she would define as a complete turn-around. Still, partway through, the Nappanee grandmother, who has battled depression most of her life with little relief from pharmaceuticals, saw a change.

"I had days of a difference where it was night and day. It was like opening my eyes for the first time," she said. "Everything was brighter, everything was new. I was thinking, 'Is this how it's really supposed to be?' Then the next day or two days, I would fall back."

But her husband said he had noticed a difference. And now, after going through the treatments last summer, Tobias can function once more.

"It's a new world for me . . . The main thing is, all you want to do is gain hope, and the rest can come later," she said. "That was my main goal, to gain hope in life."

http://www.indystar.com/article/20120429/LIVING01/204290304/When-meds-fail-magnetic-therapy-shows-promise-treating-depression

Friday, April 27, 2012

When Supplements Become Dangerous




Bulletin

When Supplements Become Dangerous

They're not as harmless as you may think

by: Peter Jaret | from: AARP Bulletin | April 4, 2012

A year after undergoing a kidney transplant, the 74-year-old patient was doing remarkably well. But when doctors reviewed his blood tests, they discovered an alarming mystery: Levels of the drug that was preventing the patient’s body from rejecting the transplanted kidney had dropped significantly. “We had no idea why at first,” says Joseph Boullata, associate professor of pharmacology and therapeutics at the University of Pennsylvania School of Nursing.

See also: Slideshow of 10 supplements that can interfere with your prescription meds — ginseng, kava, licorice and more.



When taken orally, aloe vera may interact with medicine used to treat diabetes. — Photo by ReneĆ© Comet


It wasn’t until the hospital pharmacist talked to the man’s daughter that they found the explanation. The patient had begun taking a dietary supplement that included Saint John’s wort, which is marketed to improve mood. “No one had mentioned it because no one really thought of it as a medicine,” says Boullata. But Saint John’s wort can speed the breakdown of some prescription medicines by eliminating them from the body before they can take full effect. If the blood test hadn’t alerted doctors, the supplement might have triggered rejection of the kidney — or even death.

Today, half of all Americans take dietary supplements, according to the National Institutes of Health’s Office of Dietary Supplements. Consumers spend more than $28 billion a year on vitamins, minerals and herbal remedies, in hopes that they’ll cure everything from insomnia to depression. And because many dietary supplements are touted as “natural” and are often sold in health food stores, it’s easy to assume they’re harmless.

While supplements can be harmful at any age, men and women age 50 and older are more likely to encounter problems. First, older people more often have chronic conditions like kidney or liver disease, which make it harder for the body to process compounds found in supplements. Then, too, they usually take more prescription drugs than younger people — and the more medications you take, the greater the risk of hazardous interactions with supplements.

The Food and Drug Administration regulates dietary supplements but does not apply the same rules it uses for medications. Manufacturers are not required to obtain approval from the FDA before marketing supplements. Under federal law, manufacturers are responsible for making sure their supplements are safe, and the FDA steps in only when troubles arise. Unfortunately, adverse interactions with prescription drugs may go undetected for a long time, even by physicians.

Disturbing trend

According to recent survey by the AARP Public Policy Institute, 59 percent of people 50 and older had used supplements in the previous month, and 52 percent took them daily. Fewer than half said they talked to their doctors about the pills they took.

“It’s a serious problem, and getting more serious as the number of medications and herbal products increases,” says K. Simon Yeung, a pharmacist and herbalist at Memorial Sloan-Kettering Cancer Center, where he manages a database of supplement information available to physicians and patients. According to Yeung, about 50 percent of cancer patients use some kind of dietary supplement to ease symptoms or side effects — or, out of desperation, in search of a cure.

Yeung is convinced some herbs help alleviate their symptoms. Unfortunately, several popular herbal supplements pose risks for people with cancer. Saint John’s wort, the same herb that washes antirejection drugs out of the body, can also speed the breakdown of certain cancer chemotherapies, robbing them of cancer-killing potency. And vitamin C, in megadoses, can interfere with the effectiveness of cancer drugs.

Next: Have blood clots? Beware of garlic supplements. »

Even garlic can be risky

People taking medications to prevent blood clots are vulnerable to dangerous interactions with supplements. Garlic may seem harmless, for example, but at the high doses found in supplements, garlic acts as a blood thinner. If you’re on a prescription drug to prevent blood clots, garlic supplements may make your blood too thin, increasing the risk of excessive bleeding. Ginseng, green tea supplements and vitamin K supplements can reduce the effectiveness of certain blood-thinning drugs as well.

Also at risk are patients taking drugs for depression or other psychiatric problems. Ginkgo and ginseng have both been linked to adverse interactions with psychiatric medications. Dietary supplements with psyllium, which is used as a laxative, can cause problems by reducing absorption of prescription medications, including carbamazepine and lithium, which are widely used to treat psychiatric symptoms.

The extent of the danger isn’t clear in part because so little is known about many of the active ingredients in supplements. The fact that ingredients in herbal combinations vary from batch to batch only complicates the problem. “There are 5,300 distinct dietary supplements, and very few of them have been studied systematically,” says Vanessa Grubbs, M.D., an expert in kidney disease at San Francisco General Hospital.

Grubbs began to be concerned about supplements when many of the patients coming to see her because their conditions had worsened told her they were taking them. Looking at a national health survey, Grubbs and her colleagues found that 6.5 percent of kidney patients were taking a supplement that contained one or more of 39 herbs considered to be dangerous for people with kidney problems, including nettle and sassafras.

Further, few dietary supplements have been tested to see how they interact with prescription drugs, so no one really knows which combinations are likely to cause trouble. “Pharmacologists can predict some potential interactions based on what we know about the biochemistry involved,” says Boullata. “But often we only discover there’s a problem when something bad happens.” A patient, he says, “has what looks like a heart attack or sudden unexpected changes in liver or kidney function. Eventually we discover that the cause isn’t their disease or their prescription medication but a dietary supplement they’re taking.”

And there are other hazards, such as contamination. In 2009, the FDA fingered 72 weight-loss products that contained ingredients not listed on their labels, such as traces of lead and arsenic.

Still, experts emphasize that some dietary supplements can be helpful. “Most dietary supplements are generally safe for most people at the recommended levels,” says Paul Coates, director of NIH’s Office of Dietary Supplements. He points out that supplements like calcium or vitamin B12 may be especially beneficial to people over 50 who have difficulty getting all the nutrients they need in foods.

The National Center for Complementary and Alternative Medicine also has useful information online about many commonly used dietary supplements. But the best place to start is with your doctor and pharmacist. Make sure they know if you’re taking a dietary supplement of any kind, including a multivitamin. And before you start taking any new supplement, no matter how “natural” or harmless it may seem, talk to your doctor or pharmacist.

http://www.aarp.org/health/drugs-supplements/info-04-2012/supplements-interfere-with-prescription-drugs.html

Tuesday, April 24, 2012

Two health care "stocks under rocks"

FORBES




4/17/2012 @ 4:58PM

Two health care "stocks under rocks"

The first is Cyberonics Inc. CYBX/NASDAQ), a Houston-based company that makes a medical device for the treatment of epilepsy. The tiny device, implanted in the shoulder of patients, delivers a pulse of electricity to the brain, and it’s been found to be remarkably effective for the treatment of refractory epilepsy. Patients need to exhaust other treatment methods first, but when they do the device is fully covered by insurance. Cyberonics is profitable based solely on its current U.S. business, so as the company continues to expand its international presence, I think earnings will improve.

Another upside for Cyberonics is in an entirely different line of business: depression. Research has shown that the device also produces positive results for patients with treatment-resistant forms of depression. The FDA approved the device for the treatment of depression in 2005, but when it comes to medical devices and treatments, the question isn’t just, “Does it work?” It’s “Will insurance pay for it?”

Fortunately, there’s reason to believe reimbursement for the use of the device to treat at least some forms of depression is possible, and if that happens, Cyberonics will be staring at a potential market that could far exceed the size of the epilepsy market. Cyberonics has also made an investment in Imthera Inc., a company developing a device for the treatment of sleep apnea, and when you add to that the fact that the company is also researching the use of the device to treat chronic heart failure, you have the makings of what could be a really terrific story.

The company is run by some very smart people, and at $37 a share, it appears attractively priced. Our analysts with Burkenroad Reports have a target price of $40. This growth stock sells at about 32 times our expected earnings for 2012 and represents an interesting investment based solely on the epilepsy market. If reimbursement is approved for the device’s use in the treatment of depression, it could really attract Wall Street’s attention.
http://www.forbes.com/sites/peterricchiuti/2012/04/17/two-health-care-stocks-under-rocks/

Thursday, April 19, 2012

Positive Results for Deep TMS in Major Depression

From Medscape Medical News > Psychiatry

Positive Results for Deep TMS in Major Depression

Caroline Cassels
April 18, 2012 — Results from a double-blind, multicenter, controlled trial show that deep transcranial magnetic stimulation (TMS) is safe and effective in patients with major depression.
After 5 weeks of treatment, 30.4% of patients in the active treatment group achieved remission from depression, which was defined as a Hamilton Depression Rating Scale (HDRS-21) score of less than 10. In comparison, 14.5% of the sham treatment control group achieved remission (P = .0148), according to information released by Brainsway Ltd, developers of the device used in the study.

Further, the company reports there was a significant response to treatment, defined as a greater than 50% decrease from baseline HDRS-21 scores, in 36.7% of patients in the active treatment group vs 20.5% in the control group (P = .0148).

On the basis of a US Food and Drug Administration (FDA) approved clinical trial protocol, the study included 233 patients at 14 medical centers in the United States, 4 in Israel, 2 in Germany, and 1 in Canada.

All trial participants suffered from major depression and had previously failed to respond to therapeutic treatments or could not tolerate antidepressant medication owing to side effects.

Brainsway says it expects the study results will support its application for FDA approval to market its deep TMS system for the treatment of major depression in the United States.

http://www.medscape.com/viewarticle/762249

Tuesday, April 17, 2012

Brainsway in breakthrough for depression treatment

Brainsway in breakthrough for depression treatment

The company reports that treatment with Deep TMS was found to be effective and safe, with no side effects.

17 April 12 11:54, Globes' correspondent
 
Brainsway Ltd. (TASE:BRIN) today announced good results of its multicenter trial of its Deep TMS (transcranial magnetic stimulation) device for the treatment of severe depression. The treatment was found to be effective and safe, with no side effects.
 The trial included 233 patients at four medical centers in Israel, fourteen in the US, one in Canada, and two in Germany. The patients in the trial had previously failed to respond to therapeutic treatments, or suffered from side effects of those treatments.
After five weeks of treatment, there was a statistically significant difference between the patients treated with Deep TMS and the control group, based on the Hamilton Depression Rating Scale: 30.4% of the patients treated with Deep TMS achieved remission, compared with 14.5% of the control group.
The final results of the trial will be received when the database is closed and full statistical analysis of the results is completed.
Brainsway CEO Uzi Sofer said, "We will make a presentation about the results to investors in a few days. We will submit an application to the US Food and Drug Administration (FDA) for this indication by the end the second quarter of 2012."
Since 2008, the FDA has approved use of Deep TMS up to a depth of 1.5-2 centimeters into the brain tissue, although the device can penetrate up to 6-7 centimeters to the parts of the brain that are the source of depression and addiction.
Brainsway has CE Mark for use of Deep TMS for the treatment of depression, manic-depression, and post traumatic stress syndrome. The company expects to begin marketing the device in Latin America this year. A few months ago, it obtained Israel Ministry of Health approval for use of the device for the treatment of depression, manic-depression, and schizophrenia.
Brainsway's share price rose 38.2% by midday to NIS 27.80, giving a market cap of NIS 320 million.


Monday, April 16, 2012

Vanderbilt To Study Deep Brain Stimulation For Depression

Vanderbilt To Study Deep Brain Stimulation For Depression

Released:4/16/2012 3:00 PM EDT
Source:Vanderbilt University Medical Center

Newswise — Vanderbilt University Medical Center is one of approximately 20 centers in a nationwide clinical study investigating the use of deep brain stimulation (DBS) as an intervention for patients with major depression.

BROADEN™ (BROdmann Area 25 DEep brain Neuromodulation) is the first randomized clinical research study to investigate DBS as an intervention for patients diagnosed with unipolar major depressive disorder (excluding bipolar disorder) who have not improved after multiple treatments.

DBS is a therapy that uses mild pulses of current (stimulation) to regulate specific areas of the brain, much like a pacemaker uses pulses of current to regulate the heart.

In this study, stimulation is being delivered to an area of the brain known as Brodmann Area 25, which is believed to function differently in people with major depression and appears to be overactive when people are profoundly sad and depressed.

Vanderbilt was chosen to participate in this study, which builds on the work of a research team from the University of Toronto led by Helen S. Mayberg and Andres Lozano, because of its extensive experience with various forms of neuromodulation and in treating psychiatric illness.

Ronald Salomon, M.D., associate professor of Psychiatry, is the principal investigator for the study at Vanderbilt, working with Joseph Neimat, M.D., assistant professor of Neurological Surgery, the co-investigator and neurosurgeon responsible for performing the DBS implantation procedure.

Patients enrolling in the study must be willing to transfer psychiatric care to Dr. Salomon during the course of the 14-month study.

Once the study has been completed, patients will have the option to either participate in a long-term follow-up study, return to the care of their referral psychiatrist while maintaining DBS programming-related care with a BROADEN study center, or have the DBS system removed.

The study sponsor is providing the investigational study device and study-related care at no charge to enrolled patients.

Participants must be between 21 and 70 years old, with the onset of the first episode before age 45, and currently be diagnosed with major depressive disorder.

Other criteria include being depressed for at least one year in their current episode, having tried at least four treatments in their current episode, and having tried a course of psychotherapy for depression at least once.

Participants cannot have met criteria for borderline or antisocial personality disorder in the last 12 months, cannot have GAD (Generalized Anxiety Disorder) as a primary diagnosis during the current episode, cannot have co-morbid OCD (Obsessive-Compulsive Disorder), PTSD (Post-traumatic Stress Disorder), panic disorder, or eating disorder (unless in remission for 6 months), and cannot have been diagnosed with schizophrenia, schizoaffective disorder, or other lifetime psychotic disorders.

The BROADEN study is sponsored by St. Jude Medical and is being conducted under a U.S. Food and Drug Administration (FDA) investigational device exemption (IDE). BROADEN is a trademark of Advanced Neuromodulation Systems doing business as St. Jude Medical Neuromodulation Division.

For more information about the study, please call toll-free 877-796-8732 or visit www.BroadenStudy.com.

http://www.newswise.com/articles/vanderbilt-to-study-deep-brain-stimulation-for-depression

End-of-life care: Pain control carries risk of being called a killer


PROFESSION

End-of-life care: Pain control carries risk of being called a killer

Accusations of euthanasia are common as patients, families and even other health professionals struggle to adjust to the new realities of end-of-life care.

By Kevin B. O'Reilly, amednews staff. Posted April 16, 2012.

Three decades after hospice emerged as the standard of care for terminally ill patients, the end-of-life treatments that palliative medicine physicians provide are frequently referred to as murder, euthanasia and killing.

More than half of hospice and palliative medicine physicians say patients, family members and even other health professionals have used those terms to describe care they recommended or implemented within the last five years, according to a nationwide survey of 663 palliative care doctors in the March Journal of Palliative Medicine.

Common palliative care treatments such as the use of opiates, sedatives and barbiturates to control pain and other symptoms are enough to draw accusations of murder and euthanasia, the study said. The troubling survey results come nearly six years after the American Board of Medical Specialties approved the hospice and palliative medicine subspecialty certification, and 30 years after the creation of the Medicare hospice benefit.

Nearly 1.6 million Americans received hospice care in 2010, up from about 25,000 in 1982, said the National Hospice and Palliative Care Organization. And palliative medicine has made its presence felt in hospitals, with 85% of 300-plus bed hospitals boasting palliative care teams, according to the New York City-based Center to Advance Palliative Care.

Yet the growing use of hospice and palliative care is creating more opportunities for misunderstandings, experts said. New developments in end-of-life care — aggressive pain and symptom management (even to the point of unconsciousness), along with a greater willingness to withdraw advanced, life-sustaining treatments such as mechanical ventilation, dialysis, and artificial hydration and nutrition — still strike many people as wrong.

The survey’s findings highlight the gap between the well-established ethical and legal boundaries that demarcate acceptable end-of-life care and the understanding of patients, families and other members of the health care team, experts said.

Nearly 1.6 million Americans received hospice care in 2010, up from about 25,000 in 1982.
“It’s alarming,” said H. Rex Greene, MD, a practicing oncologist and palliative medicine specialist in Lima, Ohio. “To accuse legitimate palliative care physicians of euthanasia and murder is a horrible mischaracterization of what’s done to relieve symptoms at the end of life.”

Twenty-five of the physicians surveyed said they were formally investigated by their institutions, state medical boards or prosecutors, with about half of those cases related to the use of opiates to manage dying patients’ pain. Nearly a quarter of the investigations were related to the use of palliative and sedative medications when discontinuing mechanical ventilation. An additional 8% of the investigations were for palliative sedation — the practice of sedating to unconsciousness terminally ill patients who have severe, refractory pain.

All of these treatments — when conducted with the consent of patients or surrogate decision-makers and implemented with the intent of alleviating pain or other symptoms in terminally ill patients — are broadly accepted as ethically and legally appropriate, even if they have the secondary effect of speeding the dying process.

“Physicians have an obligation to relieve pain and suffering and to promote the dignity and autonomy of dying patients in their care,” says the American Medical Association Code of Medical Ethics. “This includes providing effective palliative treatment even though it may foreseeably hasten death.”

Hard-wired misperceptions

Although none of the physicians investigated was found at fault, most reported worry, anger, anxiety, isolation, depression and difficulty working as a result of the ordeal. Euthanasia accusations — whether voiced in the patient’s room or in the courtroom — could have a chilling effect on physicians’ treatment of dying patients’ symptoms, said John G. Carney, CEO of the Center for Practical Bioethics, a Kansas City, Mo., think tank that works to improve end-of-life care.

“I’m deeply concerned that if we don’t pay attention to the message in this article, we are going to be dealing with this issue of physicians who are reluctant to do what they know to be right because they are afraid of what people will say or that someone’s going to investigate,” said Carney, a former hospice executive director.

The distinction between aggressive pain control or the withdrawal of life-sustaining treatments and euthanasia is still lost on many patients and families, physicians said.

“These misperceptions are really pretty hard-wired and difficult to eliminate,” said David Casarett, MD, chief medical officer of the University of Pennsylvania Health System’s hospice program in the Philadelphia area. “Believe me, if there were an easy way to communicate these issues, then we wouldn’t have highly qualified physicians called before medical boards to explain their actions. To some degree, this is a cultural change. We’re far ahead of where we used to be 20 years ago. On the other hand, we can’t wait another 20 years for these things to go away.”

Transformation in end-of-life care

Doctors who care care for dying patients should take into account the public’s lagging understanding of end-of-life treatments, take time to explain their intricacies and make use of ethics consultation services, said Porter Storey, MD, executive vice president of the American Academy of Hospice and Palliative Medicine.

“When I started training in this area 30 years ago, it was a rare thing to remove a feeding tube because nobody lived long enough to get that sick,” said Dr. Storey, who practices outpatient palliative care in Boulder, Colo. “Now many people are living until they are extremely debilitated on life support. And if you work in an ICU, you want to sit down and take time and talk to people, but when it’s happening every day, it’s hard to remember sometimes that the public didn’t get informed that things have changed.”

Yet confusion about end-of-life care is not limited to patients and families. A majority of the doctors surveyed said that other physicians or health professionals at times characterized their palliative care treatments as murder, euthanasia or killing.

As end-of-life care has become more specialized, the gap between what palliative care specialists see as appropriate care and other doctors’ perception of those treatments has grown, physicians said.

“Those of us in palliative care and hospice don’t think that much about putting a patient on a large dose of an opioid like morphine. We do it all the time, and we see patients do well,” said Dr. Casarett, associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania.

Recently, a patient dying of cancer enrolled in Dr. Casarett’s hospice program after deciding to stop chemotherapy treatment. The oncologist caring for the patient was upset and talked with Dr. Casarett, saying that the combination of stopping curative treatment and using high doses of opiates was wrong.

“He said, ‘We might as well just be walking away, and we might as well just shoot [the patient] now,’” Dr. Casarett recalled.

“It still stings to hear that,” he said. But Dr. Casarett takes solace in knowing that he is doing right by his patients. “I tell other physicians that this is the standard of care, and that these sorts of medications and interventions are safe and effective.”


ADDITIONAL INFORMATION:

Who’s calling palliative care “euthanasia”

More than half of palliative care doctors have been told the care they recommended or provided is “murder,” “euthanasia” or “killing.” The frequency of such accusations varies by source and at times includes other doctors.
Patient: 25%
Patient’s friend or relative: 59%
Physician’s friend or relative: 25%
Another physician: 56%
Another health professional: 57%
Source: “Prevalence of Formal Accusations of Murder and Euthanasia against Physicians,” Journal of Palliative Medicine, March (ncbi.nlm.nih.gov/pubmed/22401355/)


http://www.ama-assn.org/amednews/2012/04/16/prl20416.htm